HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy

被引：0
|
作者：
Zhao, Jing [1 ]
Zhang, Chao [2 ]
Suo, Aili [3 ]
Shi, Qiuying [4 ]
Wei, Zhimin [1 ]
Li, Zaibo [5 ]
Krishnamurti, Uma [6 ]
Li, Xiaoxian [6 ]
机构：
[1] Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China
[2] Winship Canc Inst, Atlanta, GA USA
[3] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[4] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[5] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Emory Univ, Atlanta, GA 30322 USA
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
291
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [42] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Immune Profiling of HER2 Positive TILs Rich Breast Cancer: Correlation with Response to Neoadjuvant Therapy
    Yang, Fei
    Rodriguez-Canales, Jaime
    Mino, Barbara
    Mittendorf, Elizabeth
    Sahin, Aysegul A.
    Wu, Yun
    MODERN PATHOLOGY, 2017, 30 : 79A - 79A
  • [44] Immune Profiling of HER2 Positive TILs Rich Breast Cancer: Correlation with Response to Neoadjuvant Therapy
    Yang, Fei
    Rodriguez-Canales, Jaime
    Mino, Barbara
    Mittendorf, Elizabeth
    Sahin, Aysegul A.
    Wu, Yun
    LABORATORY INVESTIGATION, 2017, 97 : 79A - 79A
  • [45] The predictive value of HER2 in breast cancer
    Piccart, M
    Lohrisch, C
    Di Leo, A
    Larsimont, D
    ONCOLOGY, 2001, 61 : 73 - 82
  • [46] Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
    Rodriguez, Mauricio
    Gonzalez, Diego M.
    El-Sharkawy, Farah
    Castano, Mileny
    Madrid, Jorge
    BIOMEDICA, 2023, 43 (03): : 396 - 405
  • [47] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [48] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [49] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [50] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Yihong Wang
    Kamaljeet Singh
    Don Dizon
    Teresa Graves
    Ali Amin
    Evgeny Yakirevich
    Breast Cancer Research and Treatment, 2021, 186 : 667 - 676
12345